1. Cantrell DA, Smith KA (1984) The interleukin-2 T-cell system: a new cell growth model. Science 224: 1312
2. Ellis TM, Creekmore SP, McMannis JD, Braun DP, Harris JA, Fisher RI (1988) Appearance and phenotypic characterization of circulating leu 19+ cells in cancer patients receiving recombinant interleukin 2. Cancer Res 48: 6597
3. Favrot MC, Combaret V, Negrier S, Philip I, Thiesse P, Freydel C, Bijmann JT, Franks CR, Mercatello A, Phillip T (1990) Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma. J Biol Response Mod 9: 167
4. Hank JA, Sosman JA, Kohler PC, Bechhofer R, Storer B, Sondel PM (1990) Depressed in vitro T cell responses concomitant with augmented interleukin-2 responses by lymphocytes from cancer patients following in vivo treatment with interleukin-2. J Biol Response Mod 9: 5
5. Hänninen EL, Körfer A, Hadam M, Schneekloth C, Dallmann I, Menzel T, Kirchner H, Poliwoda H, Atzpodien J (1991) Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes. Cancer Res 50: 6312